Close
Nordic 9Nordic 9

Cochlear Limited (investor - Corporate Investor)

Australia
See something wrong or missing? Let us know
Offices:Sydney

Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.

Average round investment:23.17M USD
Average number per year:1.0
Distribution: 2021 (1)
Portfolio companies: Germany Precisis
Mostly invests in: Germany Germany (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Cochlear Limited

Name Criteria
Germany ATHOS KG
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Cargill
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Zukunftsfonds Heilbronn
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium Fundplus
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Netherlands BioGeneration Ventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Switzerland BioMedPartners
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Luxembourg Vesalius Biocapital Partners
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Netherlands Merck Ventures
71%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 2.7
  • Active last 12 months: Yes
United States Obvious Ventures
70%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Japan Kyoritsu Holdings
70%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top